Series of Analyst Price Target Cuts Shadow Clorox Ahead of Q1 FY2027 Results

The Clorox Company (NYSE: CLX) has seen a flurry of analyst price target reductions over the past week, with multiple firms lowering expectations in advance of its upcoming first-quarter fiscal year 2027 earnings webcast on November 2.

Analyst Downgrades Intensify

In the past week, JPMorgan reduced its price target on CLX to $83 from $95 while maintaining an Underweight rating, signaling a more cautious stance on the stock’s near-term outlook. This adjustment highlights concerns around potential margin pressure and integration challenges from recent acquisitions.

Elsewhere, Deutsche Bank lowered its target to $95 from $98, keeping a Hold recommendation, and Barclays reduced its forecast to $80 from $84 while retaining an Underweight rating. UBS also trimmed its target to $91 from $105 and maintained its Neutral rating.

These price target actions reflect a broad-based reassessment of Clorox’s valuation and prospects across the brokerage community, as the company prepares to report on November 2. The adjustments span from moderate to substantial downward revisions across the board.

Context Ahead of Q1 Earnings

Clorox is set to host a webcast on November 2 to deliver its Q1 FY2027 results, which will be closely scrutinized amid concerns over organic sales, cost pressures, and debt levels following its acquisition of GOJO and integration efforts of the Purell brand.

With multiple analysts revising their targets lower, investor expectations appear tempered. The fiscal first quarter results may offer clarity on whether Clorox’s cost structure and integration strategies can support near-term recovery.

Stock Price Snapshot

As of the market close on October 27, CLX traded at $87.36, reflecting a gain of 1.39% for the day. This movement comes within a context of elevated analyst scrutiny and anticipation ahead of the earnings event.

What Investors Should Watch

• Results and commentary in the November 2 webcast, particularly on organic sales trends, whether margins improved or deteriorated, and progress integrating GOJO/Purell operations.
• Forward guidance for fiscal year 2027 and whether Clorox addresses the accumulation of analyst concerns.
• Market reaction to the earnings report, which may influence whether analysts revise their forecasts further.

With a wave of price target downgrades from major financial institutions, Clorox enters earnings season under a cloud of caution. The company’s upcoming Q1 report will be critical in shaping whether sentiment can stabilize or if further reevaluation lies ahead.